Business Context and Reporting Period
This Form 6-K filing by AMBEV S.A. covers the month of November 2021, with the report signed on November 26, 2021. The filing serves as a notice of a capital increase approved by the Board of Directors resulting from the exercise of stock options by beneficiaries under the Company's Stock Option Plan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. Instead, it details specific capitalization data related to the stock option exercises:
- Total Capital Increase: R$ 9,470,057.21
- Total New Shares Issued: 767,357 common shares (no par value)
- Issuance Price: Predominantly R$ 11.97200 per share, with some issuances at R$ 16.70000.
- Post-Issuance Capital Stock: R$ 58,015,770,638.88
- Market Price (90-day Average): R$ 16.37 (adjusted for dividends and interest on equity)
Material Changes
The primary material change reported is the increase in the Company's authorized capital and the number of issued shares due to the exercise of options granted in 2011 and 2013. The filing indicates a negligible potential dilution percentage arising from these specific issuances, ranging from 0.000132% to 0.001965% relative to the number of issued shares.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, outlook statements, or specific risk factors. The document is strictly a regulatory notice regarding the verification of share issuance and the associated capital increase.
Investor Verification Checklist
- Verify the total number of new shares issued (767,357) against the Company's updated share count.
- Confirm the issuance price of R$ 11.97200 and R$ 16.70000 aligns with the strike prices of the specific stock option plans referenced (2011 and 2013 grants).
- Review the adjusted historical market prices provided to assess the premium or discount of the exercise price relative to the market value at the time of exercise.
- Check subsequent filings for the impact of this capital increase on earnings per share (EPS) and total outstanding shares.